Replies to post #41980 on Biotech Values

[gofishmarko]

Re : DNDN & NIH meeting

Here's the link to the replays ( scroll down ; two separate 'events' ) :

http://videocast.nih.gov/PastEvents.asp?c=998

[ghmm]

They also said that treatments customized to each patient, (e.g., an anti-idiotypic antibody treatment for B cell lymphoma that targets the specific B cell causing a patient's lymphoma,) tends to work better, but is much more expensive and technically difficult to accomplish than a one-size fits all treatment (like the anti-CD20 antibody Rituxan.)

I don't follow them closely but isn't that what Favrille is doing? Not sure where they stand now but a couple months ago they had a big setback. I seem to recall another company in a similar stage (Phase 2 or 3) working on something similar too but can't recall who.